The role of cytokines and their antagonists in the treatment of COVID-19 patients
© 2022 John Wiley & Sons Ltd..
The coronavirus disease 2019 (COVID-19) has various presentations, of which immune dysregulation or the so-called cytokine storm syndrome (COVID-CSS) is prominent. Even though cytokines are vital regulators of body immunoinflammatory responses, their exaggerated release can be harmful. This hyperinflammatory response is more commonly observed during severe COVID-19 infections, caused by the excessive release of pro-inflammatory cytokines, such as interleukin-1 (IL-1), IL-6, IL-8, tumour necrosis factor, granulocyte-macrophage colony-stimulating factor, and interferon-gamma, making their blockers and antagonists of great interest as therapeutic options in this condition. Thus, the pathophysiology of excessive cytokine secretion is outlined, and their most important blockers and antagonists are discussed, mainly focussing on tocilizumab, an interleukin-6 receptor blocker approved to treat severe COVID-19 infections.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:33 |
|---|---|
| Enthalten in: |
Reviews in medical virology - 33(2023), 1 vom: 07. Jan., Seite e2372 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Mohseni Afshar, Zeinab [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
COVID-19 |
|---|
| Anmerkungen: |
Date Completed 18.01.2023 Date Revised 27.01.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1002/rmv.2372 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM34143552X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM34143552X | ||
| 003 | DE-627 | ||
| 005 | 20231226011756.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/rmv.2372 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1138.xml |
| 035 | |a (DE-627)NLM34143552X | ||
| 035 | |a (NLM)35621229 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Mohseni Afshar, Zeinab |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The role of cytokines and their antagonists in the treatment of COVID-19 patients |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 18.01.2023 | ||
| 500 | |a Date Revised 27.01.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022 John Wiley & Sons Ltd. | ||
| 520 | |a The coronavirus disease 2019 (COVID-19) has various presentations, of which immune dysregulation or the so-called cytokine storm syndrome (COVID-CSS) is prominent. Even though cytokines are vital regulators of body immunoinflammatory responses, their exaggerated release can be harmful. This hyperinflammatory response is more commonly observed during severe COVID-19 infections, caused by the excessive release of pro-inflammatory cytokines, such as interleukin-1 (IL-1), IL-6, IL-8, tumour necrosis factor, granulocyte-macrophage colony-stimulating factor, and interferon-gamma, making their blockers and antagonists of great interest as therapeutic options in this condition. Thus, the pathophysiology of excessive cytokine secretion is outlined, and their most important blockers and antagonists are discussed, mainly focussing on tocilizumab, an interleukin-6 receptor blocker approved to treat severe COVID-19 infections | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a cytokine | |
| 650 | 4 | |a tocilizumab | |
| 650 | 7 | |a Cytokines |2 NLM | |
| 700 | 1 | |a Barary, Mohammad |e verfasserin |4 aut | |
| 700 | 1 | |a Babazadeh, Arefeh |e verfasserin |4 aut | |
| 700 | 1 | |a Tavakoli Pirzaman, Ali |e verfasserin |4 aut | |
| 700 | 1 | |a Hosseinzadeh, Rezvan |e verfasserin |4 aut | |
| 700 | 1 | |a Alijanpour, Amirmasoud |e verfasserin |4 aut | |
| 700 | 1 | |a Allahgholipour, Amirreza |e verfasserin |4 aut | |
| 700 | 1 | |a Miri, Seyed Rouhollah |e verfasserin |4 aut | |
| 700 | 1 | |a Sio, Terence T |e verfasserin |4 aut | |
| 700 | 1 | |a Sullman, Mark J M |e verfasserin |4 aut | |
| 700 | 1 | |a Carson-Chahhoud, Kristin |e verfasserin |4 aut | |
| 700 | 1 | |a Ebrahimpour, Soheil |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Reviews in medical virology |d 1996 |g 33(2023), 1 vom: 07. Jan., Seite e2372 |w (DE-627)NLM090684788 |x 1099-1654 |7 nnns |
| 773 | 1 | 8 | |g volume:33 |g year:2023 |g number:1 |g day:07 |g month:01 |g pages:e2372 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/rmv.2372 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 33 |j 2023 |e 1 |b 07 |c 01 |h e2372 | ||